_id
690f3559ccc777a4e85d16d7
Ticker
BIO
Name
Bio-Rad Laboratories Inc
Exchange
NYSE
Address
1000 Alfred Nobel Drive, Hercules, CA, United States, 94547
Country
USA
Sector
Healthcare
Industry
Medical Devices
Currency
USD
Website
https://www.bio-rad.com
Description
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Last Close
313.97
Volume
126340
Current Price
308.13
Change
-1.8600503232793042
Last Updated
2025-11-28T12:53:57.547Z
Image
-
Ipo Date
1966-01-01T00:00:00.000Z
Market Cap
8821580800
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9931666666666666
Sentiment Sources
6
Rating
4
Target Price
348
Strong Buy
2
Buy
2
Hold
2
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
653000000
Cost Of Revenue
309600000
Gross Profit
343400000
Operating Expenses
278100000
Operating Income
65300000
Interest Expense
12300000
Pretax Income
-431100000
Net Income
-341900000
Eps
-12.69917914051183
Dividends Per Share
62700000
Shares Outstanding
21906399
Income Tax Expense
89200000
EBITDA
-384600000
Operating Margin
10
Total Other Income Expense Net
-496400000
Cash
397800000
Short Term Investments
1022800000
Receivables
474200000
Inventories
783200000
Total Current Assets
2842000000
Property Plant Equipment
720500000
Total Assets
9696400000
Payables
128800000
Short Term Debt
38100000
Long Term Debt
1201400000
Total Liabilities
2959600000
Equity
6736800000
Depreciation
54200000
Change In Working Capital
-14400000
Cash From Operations
120900000
Capital Expenditures
31700000
Cash From Investing
-43000000
Cash From Financing
-52500000
Net Change In Cash
26500000
PE
-
PB
1.2547521538415867
ROE
-5.075109844436527
ROA
-3.5260509054906977
FCF
89200000
Fcf Percent
0.13660030627871364
Piotroski FScore
2
Health Score
47
Deep Value Investing Score
6
Defensive Investing Score
7
Dividend Investing Score
3
Economic Moat Investing Score
6.8
Garp Investing Score
4
Growth Investing Score
3
Momentum Investing Score
3.5
Net Net Investing Score
2.5
Quality Investing Score
6
Value Investing Score
5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
653000000
Quarters > 0 > income Statement > cost Of Revenue
309600000
Quarters > 0 > income Statement > gross Profit
343400000
Quarters > 0 > income Statement > operating Expenses
278100000
Quarters > 0 > income Statement > operating Income
65300000
Quarters > 0 > income Statement > interest Expense
12300000
Quarters > 0 > income Statement > pretax Income
-431100000
Quarters > 0 > income Statement > net Income
-341900000
Quarters > 0 > income Statement > eps
-12.69917914051183
Quarters > 0 > income Statement > dividends Per Share
62700000
Quarters > 0 > income Statement > shares Outstanding
26923000
Quarters > 0 > income Statement > income Tax Expense
89200000
Quarters > 0 > income Statement > EBITDA
-384600000
Quarters > 0 > income Statement > operating Margin
10
Quarters > 0 > income Statement > total Other Income Expense Net
-496400000
Quarters > 0 > balance Sheet > cash
397800000
Quarters > 0 > balance Sheet > short Term Investments
1022800000
Quarters > 0 > balance Sheet > receivables
474200000
Quarters > 0 > balance Sheet > inventories
783200000
Quarters > 0 > balance Sheet > total Current Assets
2842000000
Quarters > 0 > balance Sheet > property Plant Equipment
720500000
Quarters > 0 > balance Sheet > total Assets
9696400000
Quarters > 0 > balance Sheet > payables
128800000
Quarters > 0 > balance Sheet > short Term Debt
38100000
Quarters > 0 > balance Sheet > long Term Debt
1201400000
Quarters > 0 > balance Sheet > total Liabilities
2959600000
Quarters > 0 > balance Sheet > equity
6736800000
Quarters > 0 > cash Flow > net Income
-341900000
Quarters > 0 > cash Flow > depreciation
54200000
Quarters > 0 > cash Flow > change In Working Capital
-14400000
Quarters > 0 > cash Flow > cash From Operations
120900000
Quarters > 0 > cash Flow > capital Expenditures
31700000
Quarters > 0 > cash Flow > cash From Investing
-43000000
Quarters > 0 > cash Flow > cash From Financing
-52500000
Quarters > 0 > cash Flow > net Change In Cash
26500000
Quarters > 0 > ratios > PE
-12.69917914051183
Quarters > 0 > ratios > PB
1.2547521538415867
Quarters > 0 > ratios > ROE
-5.075109844436527
Quarters > 0 > ratios > ROA
-3.5260509054906977
Quarters > 0 > ratios > FCF
89200000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
0.13660030627871364
Quarters > 0 > health Score
47
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
651600000
Quarters > 1 > income Statement > cost Of Revenue
306300000
Quarters > 1 > income Statement > gross Profit
345300000
Quarters > 1 > income Statement > operating Expenses
268200000
Quarters > 1 > income Statement > operating Income
77100000
Quarters > 1 > income Statement > interest Expense
12600000
Quarters > 1 > income Statement > pretax Income
414000000
Quarters > 1 > income Statement > net Income
317800000
Quarters > 1 > income Statement > eps
11.67180843249596
Quarters > 1 > income Statement > dividends Per Share
48900000
Quarters > 1 > income Statement > shares Outstanding
27228000
Quarters > 1 > income Statement > income Tax Expense
96200000
Quarters > 1 > income Statement > EBITDA
477200000
Quarters > 1 > income Statement > operating Margin
11.832412523020258
Quarters > 1 > income Statement > total Other Income Expense Net
336900000
Quarters > 1 > balance Sheet > cash
369300000
Quarters > 1 > balance Sheet > short Term Investments
1004500000
Quarters > 1 > balance Sheet > receivables
469900000
Quarters > 1 > balance Sheet > inventories
798800000
Quarters > 1 > balance Sheet > total Current Assets
2811100000
Quarters > 1 > balance Sheet > property Plant Equipment
740100000
Quarters > 1 > balance Sheet > total Assets
10214100000
Quarters > 1 > balance Sheet > payables
139300000
Quarters > 1 > balance Sheet > short Term Debt
40600000
Quarters > 1 > balance Sheet > long Term Debt
1201100000
Quarters > 1 > balance Sheet > total Liabilities
3085400000
Quarters > 1 > balance Sheet > equity
7128700000
Quarters > 1 > cash Flow > net Income
-120100000
Quarters > 1 > cash Flow > depreciation
-38100000
Quarters > 1 > cash Flow > change In Working Capital
-43600000
Quarters > 1 > cash Flow > cash From Operations
116500000
Quarters > 1 > cash Flow > capital Expenditures
45700000
Quarters > 1 > cash Flow > cash From Investing
-115400000
Quarters > 1 > cash Flow > cash From Financing
-136300000
Quarters > 1 > cash Flow > net Change In Cash
-151400000
Quarters > 1 > ratios > PE
11.67180843249596
Quarters > 1 > ratios > PB
1.199205347398544
Quarters > 1 > ratios > ROE
4.458035827009132
Quarters > 1 > ratios > ROA
3.111385241969434
Quarters > 1 > ratios > FCF
70800000
Quarters > 1 > ratios > Piotroski FScore
3
Quarters > 1 > ratios > fcf Percent
0.10865561694290976
Quarters > 1 > health Score
63
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
585400000
Quarters > 2 > income Statement > cost Of Revenue
279400000
Quarters > 2 > income Statement > gross Profit
306000000
Quarters > 2 > income Statement > operating Expenses
282300000
Quarters > 2 > income Statement > operating Income
23700000
Quarters > 2 > income Statement > interest Expense
12000000
Quarters > 2 > income Statement > pretax Income
83400000
Quarters > 2 > income Statement > net Income
64000000
Quarters > 2 > income Statement > eps
2.2893936683956357
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
27955000
Quarters > 2 > income Statement > income Tax Expense
19400000
Quarters > 2 > income Statement > EBITDA
133500000
Quarters > 2 > income Statement > operating Margin
4.04851383669286
Quarters > 2 > income Statement > total Other Income Expense Net
59700000
Quarters > 2 > balance Sheet > cash
521400000
Quarters > 2 > balance Sheet > short Term Investments
1139000000
Quarters > 2 > balance Sheet > receivables
424700000
Quarters > 2 > balance Sheet > inventories
790100000
Quarters > 2 > balance Sheet > total Current Assets
3036600000
Quarters > 2 > balance Sheet > property Plant Equipment
681700000
Quarters > 2 > balance Sheet > total Assets
9526900000
Quarters > 2 > balance Sheet > payables
137900000
Quarters > 2 > balance Sheet > short Term Debt
42500000
Quarters > 2 > balance Sheet > long Term Debt
1200700000
Quarters > 2 > balance Sheet > total Liabilities
2847500000
Quarters > 2 > balance Sheet > equity
6679400000
Quarters > 2 > cash Flow > net Income
64000000
Quarters > 2 > cash Flow > depreciation
38100000
Quarters > 2 > cash Flow > change In Working Capital
43600000
Quarters > 2 > cash Flow > cash From Operations
129900000
Quarters > 2 > cash Flow > capital Expenditures
34400000
Quarters > 2 > cash Flow > cash From Investing
2900000
Quarters > 2 > cash Flow > cash From Financing
-97700000
Quarters > 2 > cash Flow > net Change In Cash
33300000
Quarters > 2 > ratios > PE
2.2893936683956357
Quarters > 2 > ratios > PB
1.31404487678534
Quarters > 2 > ratios > ROE
0.9581698954995956
Quarters > 2 > ratios > ROA
0.6717820067388133
Quarters > 2 > ratios > FCF
95500000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.1631363170481722
Quarters > 2 > health Score
67
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
667475000
Quarters > 3 > income Statement > cost Of Revenue
325563000
Quarters > 3 > income Statement > gross Profit
341912000
Quarters > 3 > income Statement > operating Expenses
283582000
Quarters > 3 > income Statement > operating Income
58330000
Quarters > 3 > income Statement > interest Expense
12185000
Quarters > 3 > income Statement > pretax Income
-908900000
Quarters > 3 > income Statement > net Income
-715800000
Quarters > 3 > income Statement > eps
-25.56702503839697
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
27997000
Quarters > 3 > income Statement > income Tax Expense
-193100000
Quarters > 3 > income Statement > EBITDA
-847400000
Quarters > 3 > income Statement > operating Margin
8.738904078804449
Quarters > 3 > income Statement > total Other Income Expense Net
-967230000
Quarters > 3 > balance Sheet > cash
488100000
Quarters > 3 > balance Sheet > short Term Investments
1176400000
Quarters > 3 > balance Sheet > receivables
452500000
Quarters > 3 > balance Sheet > inventories
760000000
Quarters > 3 > balance Sheet > total Current Assets
3030300000
Quarters > 3 > balance Sheet > property Plant Equipment
688600000
Quarters > 3 > balance Sheet > total Assets
9364100000
Quarters > 3 > balance Sheet > payables
122300000
Quarters > 3 > balance Sheet > short Term Debt
42900000
Quarters > 3 > balance Sheet > long Term Debt
1200400000
Quarters > 3 > balance Sheet > total Liabilities
2794800000
Quarters > 3 > balance Sheet > equity
6569300000
Quarters > 3 > cash Flow > net Income
-715800000
Quarters > 3 > cash Flow > depreciation
49300000
Quarters > 3 > cash Flow > change In Working Capital
56954000
Quarters > 3 > cash Flow > cash From Operations
124152000
Quarters > 3 > cash Flow > capital Expenditures
42904000
Quarters > 3 > cash Flow > cash From Investing
-30544000
Quarters > 3 > cash Flow > cash From Financing
-26248000
Quarters > 3 > cash Flow > net Change In Cash
77612000
Quarters > 3 > ratios > PE
-25.56702503839697
Quarters > 3 > ratios > PB
1.3380753033047663
Quarters > 3 > ratios > ROE
-10.896138096905302
Quarters > 3 > ratios > ROA
-7.644087525763288
Quarters > 3 > ratios > FCF
81248000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
0.1217244091539009
Quarters > 3 > health Score
46
Valuation > metrics > PE
-12.69917914051183
Valuation > metrics > PB
1.2547521538415867
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-5.075109844436527
Profitability > metrics > ROA
-12.030260380014074
Profitability > metrics > Net Margin
-0.5235834609494641
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.4393183707398171
Risk > metrics > Interest Coverage
5.308943089430894
Risk > final Score
81
Risk > verdict
Low
Liquidity > metrics > Current Ratio
17.02816057519473
Liquidity > metrics > Quick Ratio
12.335530257639306
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
100
Prev Valuations > 2
80
Prev Profitabilities > 0
69
Prev Profitabilities > 1
25
Prev Profitabilities > 2
0
Prev Risks > 0
84
Prev Risks > 1
68
Prev Risks > 2
79
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T14:18:17.795Z
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ASelling Bio Green Med Solution Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders simplywall.st
Read more →Bain Capital Life Sciences Investors LLC Raises Holdings in Upstream Bio, Inc. $UPB - MarketBeat
12/13/2025
Bain Capital Life Sciences Investors LLC Raises Holdings in Upstream Bio, Inc. $UPB MarketBeat
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$348
Analyst Picks
Strong Buy
2
Buy
2
Hold
2
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 50.26% of the total shares of Bio-Rad Laboratories Inc
1.
Arnhold & S. Bleichroeder Advisers, LLC(9.3019%)
since
2025/06/30
2.
Vanguard Group Inc(6.8233%)
since
2025/06/30
3.
BlackRock Inc(6.5133%)
since
2025/06/30
4.
Dimensional Fund Advisors, Inc.(3.6936%)
since
2025/06/30
5.
Veritas Asset Management LLP(3.1894%)
since
2025/06/30
6.
Ariel Investments, LLC(3.0249%)
since
2025/06/30
7.
Earnest Partners LLC(2.2388%)
since
2025/06/30
8.
State Street Corp(2.1593%)
since
2025/06/30
9.
Bank of America Corp(1.6707%)
since
2025/06/30
10.
First Pacific Advisors, LP(1.4298%)
since
2025/06/30
11.
Geode Capital Management, LLC(1.2347%)
since
2025/06/30
12.
Parnassus Investments LLC(1.1722%)
since
2025/06/30
13.
Southeastern Asset Management Inc(1.165%)
since
2025/06/30
14.
Thompson, Siegel & Walmsley LLC(1.1312%)
since
2025/06/30
15.
Mawer Investment Management Ltd(0.987%)
since
2025/06/30
16.
SEI Investments Co(0.9806%)
since
2025/06/30
17.
Select Equity Group LP(0.9459%)
since
2025/06/30
18.
Millennium Management LLC(0.9306%)
since
2025/06/30
19.
Northern Trust Corp(0.837%)
since
2025/06/30
20.
Deerfield Management Co(0.8354%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.